Showing results (291-300 of 323) with videos related to
Sort By:
Pageof 33
European Journal of Cancer (Oxford, England : 1990)|August 21, 2020
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancerClaudia Cardone, Bernadette Blauensteiner, Veronica Moreno-Viedma, et al.The Lancet. Oncology|November 18, 2024
Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trialGiovanni Randon, Sara Lonardi, Matteo Fassan, et al.Cancers|April 3, 2021
Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort StudySerena Di Cosimo, Barbara Tagliaferri, Daniele Generali, et al.Nature Medicine|September 13, 2022
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF<sup>V600E</sup> metastatic colorectal cancerElena Elez, Javier Ros, Jose Fernández, et al.Cancers|July 2, 2021
TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY StudyAlessandra Raimondi, Federica Palermo, Michele Prisciandaro, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2022
Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global ExperienceSteven B Maron, Stephanie Moya, Federica Morano, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2022
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O<sup>6</sup>-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA TrialFederica Morano, Alessandra Raimondi, Filippo Pagani, et al.Journal of the National Cancer Institute|January 26, 2018
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal CancerFilippo Pietrantonio, Federica Di Nicolantonio, Alexa B Schrock, et al.The Lancet. Oncology|May 31, 2022
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trialCarlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio, et al.Cancer Research|May 2, 2023
BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP InhibitorsAnnalisa Petrelli, Sabrina Rizzolio, Filippo Pietrantonio, et al.Pageof 33